JP2017509684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509684A5 JP2017509684A5 JP2016560802A JP2016560802A JP2017509684A5 JP 2017509684 A5 JP2017509684 A5 JP 2017509684A5 JP 2016560802 A JP2016560802 A JP 2016560802A JP 2016560802 A JP2016560802 A JP 2016560802A JP 2017509684 A5 JP2017509684 A5 JP 2017509684A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rapamycin
- amount
- micrograms
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 50
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 40
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 39
- 229960002930 sirolimus Drugs 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 20
- 210000004072 lung Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000000443 aerosol Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 239000011888 foil Substances 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920003023 plastic Polymers 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 239000013011 aqueous formulation Substances 0.000 description 5
- 238000001238 wet grinding Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975127P | 2014-04-04 | 2014-04-04 | |
| US61/975,127 | 2014-04-04 | ||
| PCT/US2015/024551 WO2015154084A1 (en) | 2014-04-04 | 2015-04-06 | An inhalable rapamycin formulation for treating age-related conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083679A Division JP2019142934A (ja) | 2014-04-04 | 2019-04-25 | 加齢関連状態を処置するための吸入可能なラパマイシン配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509684A JP2017509684A (ja) | 2017-04-06 |
| JP2017509684A5 true JP2017509684A5 (cg-RX-API-DMAC7.html) | 2018-05-17 |
| JP6525285B2 JP6525285B2 (ja) | 2019-06-05 |
Family
ID=53005668
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560802A Active JP6525285B2 (ja) | 2014-04-04 | 2015-04-06 | 加齢関連状態を処置するための吸入可能なラパマイシン配合物 |
| JP2019083679A Pending JP2019142934A (ja) | 2014-04-04 | 2019-04-25 | 加齢関連状態を処置するための吸入可能なラパマイシン配合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083679A Pending JP2019142934A (ja) | 2014-04-04 | 2019-04-25 | 加齢関連状態を処置するための吸入可能なラパマイシン配合物 |
Country Status (21)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
| MX381173B (es) | 2013-10-08 | 2025-03-12 | Ai Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| MX394266B (es) | 2014-04-04 | 2025-03-24 | Ai Therapeutics Inc | Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. |
| WO2016057712A1 (en) * | 2014-10-07 | 2016-04-14 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| MA40910A (fr) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| PT109117B (pt) * | 2016-01-28 | 2019-02-01 | Hovione Farm Sa | Complexação de ingredientes ativos farmacêuticos |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| CN108926533B (zh) * | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| HRP20221361T1 (hr) * | 2020-05-18 | 2023-01-06 | Orexo Ab | Novi farmaceutski sastav za davanje lijeka |
| AU2020277132B1 (en) * | 2020-11-24 | 2021-11-04 | Aft Pharmaceuticals Limited | A Rapamycin Composition |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| WO2023094826A1 (en) | 2021-11-25 | 2023-06-01 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
| CN114796208B (zh) * | 2022-05-27 | 2024-01-23 | 上海海洋大学 | 雷帕霉素在制备预防或治疗鲫造血器官坏死病药物中的应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2517482A (en) | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
| GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| DE3345722A1 (de) | 1983-12-17 | 1985-06-27 | Boehringer Ingelheim KG, 6507 Ingelheim | Inhalator |
| GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| DE4140689B4 (de) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| MX9702357A (es) | 1994-09-29 | 1997-06-28 | Andaris Ltd | Microparticulas secadas por aspersion como vehiculos terapeuticos. |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| DE19523516C1 (de) | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| BR9713661A (pt) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulação e método para o tratamento de neoplasmas por inalação |
| US6451784B1 (en) | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US20040039047A1 (en) | 1998-08-11 | 2004-02-26 | Mark Zamoyski | Compositions and methods for treating lung cancers |
| EP1104760B1 (en) | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| EP1424898A4 (en) | 2001-08-20 | 2008-04-02 | Transave Inc | TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM |
| JP2005502653A (ja) | 2001-08-20 | 2005-01-27 | トランセーヴ・インコーポレーテッド | 肺ガンの治療方法 |
| EP1506032A1 (en) | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| US20050070567A1 (en) | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| AU2003269989B8 (en) | 2002-08-21 | 2009-11-12 | Norton Healthcare Ltd. | Inhalation composition |
| SI1585548T1 (sl) * | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| UA83484C2 (uk) | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| AR050374A1 (es) | 2004-08-20 | 2006-10-18 | Wyeth Corp | Forma polimorfica de rafampicina |
| CN101076319A (zh) | 2004-09-29 | 2007-11-21 | 科迪斯公司 | 稳定的非晶形雷帕霉素样化合物的药物剂型 |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| FR2882366B1 (fr) | 2005-02-18 | 2008-04-18 | Coletica Sa | Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols |
| CA2599582A1 (en) | 2005-03-02 | 2006-09-08 | Wyeth | Purification of rapamycin |
| BRPI0608573A2 (pt) | 2005-03-08 | 2017-07-25 | Lifecycle Pharma As | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
| CA2601312A1 (en) | 2005-03-17 | 2006-09-28 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| CN1883474A (zh) | 2005-06-22 | 2006-12-27 | 华北制药集团新药研究开发有限责任公司 | 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物 |
| US7446096B2 (en) | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
| EP1962819A1 (en) | 2005-12-20 | 2008-09-03 | Wyeth | Control of cci-779 dosage form stability through control of drug substance impurities |
| GB0602123D0 (en) | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
| ES2672627T3 (es) | 2006-02-02 | 2018-06-15 | Novartis Ag | Tratamiento de la esclerosis tuberosa |
| WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| BRPI0621967A2 (pt) * | 2006-11-10 | 2011-12-27 | Biocon Ltd | forma pura de rapamicina e um processo para recuperaÇço e purificaÇço da mesma |
| EP2092942A1 (en) | 2006-11-20 | 2009-08-26 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414909B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080138405A1 (en) | 2006-12-06 | 2008-06-12 | Raheja Praveen | Sirolimus nanodispersion |
| EP1952807A1 (en) | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| AU2008218806B2 (en) | 2007-02-20 | 2011-12-01 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mTOR inhibitors |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2009214443B2 (en) | 2008-02-13 | 2013-10-10 | Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| EP2365802B1 (en) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| WO2010085780A1 (en) | 2009-01-26 | 2010-07-29 | Teva Pharmaceutical Industries Ltd. | Processes for coating a carrier with microparticles |
| US20100196483A1 (en) * | 2009-02-04 | 2010-08-05 | Activaero Gmbh Research & Development | Method for treatmentof severe and uncontrollable asthma |
| GB0905818D0 (en) | 2009-04-06 | 2009-05-20 | Airbus Uk Ltd | Coupling assembly |
| CN102612564B (zh) | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
| GB0908129D0 (en) | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| US9248110B2 (en) | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| PT105058B (pt) | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| WO2011163600A2 (en) | 2010-06-25 | 2011-12-29 | Apt Pharmaceuticals, Inc. | Tacrolimus compositions for aerosol administration |
| US20140037548A1 (en) | 2010-06-28 | 2014-02-06 | The Board Of Trustees Of The Leland Standford Junior University | Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors |
| WO2012047674A2 (en) | 2010-09-27 | 2012-04-12 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
| CN102670518B (zh) | 2011-03-14 | 2014-08-20 | 齐鲁制药有限公司 | 一种难溶性药物球形颗粒的制备方法 |
| US20140067548A1 (en) | 2012-08-31 | 2014-03-06 | Sap Ag | Saving on device functionality for business calendar |
| JP2016522006A (ja) | 2013-03-28 | 2016-07-28 | エンドチョイス インコーポレイテッドＥｎｄｏｃｈｏｉｃｅ， Ｉｎｃ． | 小型マルチビュー素子内視鏡システム |
| MX381173B (es) | 2013-10-08 | 2025-03-12 | Ai Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| EP3104891A1 (en) | 2014-02-11 | 2016-12-21 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| MX394266B (es) | 2014-04-04 | 2025-03-24 | Ai Therapeutics Inc | Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. |
| DE102014005466A1 (de) | 2014-04-12 | 2015-10-15 | Klaus Düring | Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps |
| WO2016057712A1 (en) | 2014-10-07 | 2016-04-14 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) * | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| CN108039392A (zh) | 2017-11-06 | 2018-05-15 | 北京汉能薄膜发电技术有限公司 | 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法 |
-
2015
- 2015-04-06 MX MX2016012712A patent/MX394266B/es unknown
- 2015-04-06 KR KR1020167029824A patent/KR102352249B1/ko active Active
- 2015-04-06 EP EP23162835.5A patent/EP4218742A1/en not_active Withdrawn
- 2015-04-06 JP JP2016560802A patent/JP6525285B2/ja active Active
- 2015-04-06 HR HRP20230863TT patent/HRP20230863T1/hr unknown
- 2015-04-06 WO PCT/US2015/024551 patent/WO2015154084A1/en not_active Ceased
- 2015-04-06 DK DK15718687.5T patent/DK3125875T3/da active
- 2015-04-06 PT PT157186875T patent/PT3125875T/pt unknown
- 2015-04-06 AU AU2015240485A patent/AU2015240485B2/en active Active
- 2015-04-06 BR BR112016022598A patent/BR112016022598A8/pt not_active Application Discontinuation
- 2015-04-06 PL PL15718687.5T patent/PL3125875T3/pl unknown
- 2015-04-06 EP EP15718687.5A patent/EP3125875B1/en active Active
- 2015-04-06 RS RS20230673A patent/RS64482B1/sr unknown
- 2015-04-06 NZ NZ724756A patent/NZ724756A/en unknown
- 2015-04-06 RU RU2016143365A patent/RU2718583C2/ru active
- 2015-04-06 CA CA2944075A patent/CA2944075C/en active Active
- 2015-04-06 HU HUE15718687A patent/HUE062742T2/hu unknown
- 2015-04-06 ES ES15718687T patent/ES2952025T3/es active Active
- 2015-04-06 FI FIEP15718687.5T patent/FI3125875T3/fi active
- 2015-04-06 US US15/301,252 patent/US20170014341A1/en not_active Abandoned
- 2015-04-06 CN CN201580029505.3A patent/CN106659686A/zh active Pending
-
2016
- 2016-09-26 IL IL248048A patent/IL248048A0/en unknown
- 2016-09-28 MX MX2022004103A patent/MX2022004103A/es unknown
-
2018
- 2018-07-23 US US16/042,534 patent/US11103449B2/en active Active
-
2019
- 2019-04-25 JP JP2019083679A patent/JP2019142934A/ja active Pending
-
2021
- 2021-03-31 US US17/301,316 patent/US11648199B2/en active Active
-
2023
- 2023-04-10 US US18/132,743 patent/US20230240986A1/en not_active Abandoned
-
2024
- 2024-04-23 US US18/643,988 patent/US20240285524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509684A5 (cg-RX-API-DMAC7.html) | ||
| Weber et al. | Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art | |
| JP2016532672A5 (cg-RX-API-DMAC7.html) | ||
| JP2022088592A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
| JP2021102620A (ja) | 乾燥粉末配合および使用方法 | |
| US11291648B2 (en) | Powdered formulations of cromolyn sodium and alpha-lactose | |
| TW200817047A (en) | Drug microparticles | |
| KR20160141776A (ko) | 연령 관련 병태를 치료하기 위한 흡입가능한 라파마이신 제제 | |
| KR20160120739A (ko) | 림프관평활근종증의 치료를 위한 라파마이신 | |
| KR20160088300A (ko) | 림프관평활근종증의 치료를 위한 라파마이신 | |
| CN107205936B (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
| JP2017534604A5 (cg-RX-API-DMAC7.html) | ||
| TW200916126A (en) | Organic compounds | |
| KR20170095807A (ko) | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| CN113271960A (zh) | 干粉吸入配制品及其用于治疗肺的用途 | |
| Ozeki et al. | Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation | |
| KR20100095437A (ko) | 아스코르브산 유도체를 포함하는 건조 분말 제제 | |
| JP2023551798A (ja) | 血管新生阻害剤を含む吸入可能な乾燥粉末製剤 | |
| JP2013082660A (ja) | ニコチン薬の製造法およびその方法により製造される医薬 | |
| Kanojia et al. | Recent advancements and applications of inhalable microparticles based drug delivery systems in respiratory disorders | |
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| CN103347518A (zh) | 含有抗毒蕈碱药物的无推进剂液体制剂 | |
| KR20170039255A (ko) | 흡입용 건조 분말 제형 | |
| JP2021522325A (ja) | 真菌感染症の治療方法 |